Patents Represented by Attorney, Agent or Law Firm Henry P. Nowak
  • Patent number: 6376746
    Abstract: The invention relates to plants, seeds and DNA constructs containing DNA that is either SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9, or the complementary or double stranded sequence thereof, as well as a method for their preparation.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: April 23, 2002
    Assignee: Paradigm Genetics, Inc.
    Inventor: Andreas S. Kloti
  • Patent number: 6360482
    Abstract: A spray booth is provided for reproducible application of agrichemicals to plants. The spray booth comprises a support member for supporting a plurality of plants, a cover having a plurality of sides and a top and forming an enclosure with the support member for enclosing the plants therein, an agrichemical source for providing a pressurized agrichemical, and a spray arm having a spray mechanism operably connected to the agrichemical source. Preferably, the spray arm is disposed within the enclosure and over the support member such that it extends across the width of the support member. The spray mechanism is used for spraying a predetermined amount of the agrichemical therefrom in the form of a fine mist along the length of the spray arm. Advantageously, at least one of the support member and the spray arm is laterally moveable relative to the other such that the plants disposed both lengthwise and widthwise on the support member are substantially uniformly misted with the agrichemical.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: March 26, 2002
    Assignee: Paradigm Genetics, Inc.
    Inventor: Douglas C. Boyes
  • Patent number: 6353155
    Abstract: A method for preparing transgenic plants and seeds is claimed. The method is particularly useful for high-throughput transformation of plants, such as Arabidopsis thaliana, using many different types of DNA sequences of interest.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: March 5, 2002
    Assignee: Paradigm Genetics, Inc.
    Inventors: Andreas S. Klöti, Rao Mulpuri
  • Patent number: 6331663
    Abstract: This invention relates to plants, seeds and DNA constructs containing DNA that is either SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:20, or the complementary or double stranded sequence thereof, as well as a method for their preparation.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: December 18, 2001
    Assignee: Paradigm Genetics, Inc.
    Inventor: Andreas S. Kloti
  • Patent number: 6140071
    Abstract: This invention relates to proteins with N-terminal modifications in their amino acid sequence that reduce or eliminate the methylation of the N-terminal methionine that occurs when such proteins are produced in bacteria such as E. coli.
    Type: Grant
    Filed: January 27, 1994
    Date of Patent: October 31, 2000
    Assignee: Somatogen, Inc.
    Inventors: Jacqueline F. Aitken, Izydor Z. Apostol, Julie A. Lippincott, Joseph D. Levine
  • Patent number: 6096720
    Abstract: A pharmaceutical composition comprising (A) an oligonucleotide 8 to 50 nucleotides in length, which is targeted to mRNA encoding human raf and is capable of inhibiting raf expression, entrapped in (B) sterically stabilized liposomes.
    Type: Grant
    Filed: April 23, 1998
    Date of Patent: August 1, 2000
    Assignee: Novartis AG
    Inventors: William Guy Love, Paul Leslie Nicklin, Karen Ophelia Hamilton, Judith Ann Phillips
  • Patent number: 6020153
    Abstract: The invention relates to murine/human chimeric monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the preparation of these antibodies and their derivatives, DNAs coding for heavy and light chains of these antibodies, processes for the preparation of said DNAs, mammalian cell lines that produce and secrete the antibodies and processes for the preparation of said cell lines. The chimeric antibodies and their derivatives are used for clinical purposes in vitro and in vivo, especially for the diagnosis of cancer, for localization and in vivo imaging of tumors, for therapy, e.g. site-directed delivery of cytotoxins, and similar purposes. The invention also concerns test kits and pharmaceutical compositions containing said chimeric monoclonal antibodies and/or derivatives thereof.
    Type: Grant
    Filed: September 16, 1994
    Date of Patent: February 1, 2000
    Assignee: Ciba-Geigy Corporation
    Inventors: Norman Hardman, Laura Lee Gill, Ronald F. J. de Winter, Kathrin Wagner, Christoph Heusser
  • Patent number: 5922569
    Abstract: The invention concerns a method for the production of a polypeptide with the aid of genetically engineered yeast cells which contain not more than one functional CUP1 gene in the genome and carry a plasmid comprising a gene coding for said polypeptide and a functional CUP1 gene; and said yeast cells and said plasmids.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: July 13, 1999
    Assignee: Ciba-Geigy Corporation
    Inventors: Jutta Heim, Thomas Hottiger, Gabriele Pohlig, Peter Furst
  • Patent number: 5843708
    Abstract: The invention relates to murine/human chimeric monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the preparation of these antibodies and their derivatives, DNAs coding for heavy and light chains of these antibodies, processes for the preparation of said DNAs, mammalian cell lines that produce and secrete the antibodies and processes for the preparation of said cell lines. The chimeric antibodies and their derivatives are used for clinical purposes in vitro and in vivo, especially for the diagnosis of cancer, for localization and in vivo imaging of tumors, for therapy, e.g. site-directed delivery of cytotoxins, and similar purposes. The invention also concerns test kits and pharmaceutical compositions containing said chimeric monoclonal antibodies and/or derivatives thereof.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 1, 1998
    Assignee: CIBA-GEIGY Corporation
    Inventors: Norman Hardman, Laura Lee Gill, Ronald F.J. de Winter, Kathrin Wagner, Christoph Heusser
  • Patent number: 5843676
    Abstract: The invention relates to novel purified human immunoglobulin E binding factors (IgE-BFs), its individual optionally glycosylated proteins, and fragments thereof, processes for the purification of IgE-BFs, novel monoclonal antibodies to lymphocyte cellular receptors for IgE (Fc.sub..epsilon. R) crossreacting with IgE-BFs, derivatives thereof, processes for the preparation of these antibodies and their derivatives, hybridoma cell lines that produce these antibodies, processes for the preparation of said hybridoma cell lines, the use of the monoclonal antibodies and their derivatives for the qualitative and quantitative determination of IgE-BFs, test kits containing the monoclonal antibodies and/or their derivatives, the use of the monoclonal antibodies for the purification of IgE-BFs, the use of purified IgE-BFs, its individual optionally glycosylated proteins and/or fragments thereof for the prevention and/or treatment of allergy, and to pharmaceutical preparations containing them.
    Type: Grant
    Filed: May 16, 1996
    Date of Patent: December 1, 1998
    Assignee: Ciba-Geigy Corporation
    Inventor: Guy Delespesse
  • Patent number: 5804417
    Abstract: The invention lies in the field of genetic engineering and, in particular, is concerned with the use of 7B2 as chaperone in vivo or in vitro. The invention accordingly concerns a method for producing a desired protein in vivo with the aid of recombinant cells capable of expressing 7B2 and of expressing and secreting said desired protein. Another aspect is accordingly an in vitro method for the deaggregation or prevention of aggregation of protein by treating the protein with 7B2.
    Type: Grant
    Filed: September 9, 1996
    Date of Patent: September 8, 1998
    Assignee: Novartis Corporation
    Inventors: Gerardus Julianus Maria Martens, Bhabatosh Chaudhuri, Christine Stephan
  • Patent number: 5744460
    Abstract: The invention relates to combinations of PKC-targeted (especially PKC-.alpha.-targeted) deoxyribo- and ribo-oligonucleotides and derivatives thereof with other chemotherapeutic compounds, as well as to pharmaceutical preparations and/or therapies, in relation to disease states which respond to such oligonucleotides or oligonucleotide derivatives, especially to to modulation of the activity of a regulatory protein.
    Type: Grant
    Filed: March 7, 1996
    Date of Patent: April 28, 1998
    Assignee: Novartis Corporation
    Inventors: Marcel Muller, Thomas Geiger, Karl-Heinz Altmann, Doriano Fabbro, Nicholas M. Dean, Brett Monia, Clarence Frank Bennett
  • Patent number: 5733874
    Abstract: The present invention provides a freeze dried pharmaceutical composition comprising hirudin and a water-soluble salt of calcium and/or magnesium.
    Type: Grant
    Filed: January 25, 1995
    Date of Patent: March 31, 1998
    Assignee: Novartis Corp.
    Inventor: Tudor Arvinte
  • Patent number: 5728549
    Abstract: The invention relates to DNA sequences that code for the amino acid sequence of the thrombin inhibitor hirudin, hybrid vectors containing such DNA sequences, host cells transformed with such hybrid vectors, novel polypeptides with thrombin-inhibiting activity produced from such transformed host cells, processes for the manufacture of these DNA sequences, hybrid vectors and transformed host cells, and processes for the manufacture of these thrombin-inhibitors using the transformed host cells. The hirudin compounds that can be produced according to the invention have valuable pharmacological properties.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: March 17, 1998
    Assignee: Novartis Corporation
    Inventors: Manfred Liersch, Hans Rink, Walter Marki, Markus Gerhard Grutter, Bernd Meyhack
  • Patent number: 5726043
    Abstract: A novel process for the production of recombinant desulphatohirudin by transformed yeast strains is provided. The process makes use of an expression cassette comprising the yeast CUP1 promoter. The invention concerns also said transformed yeast strains, novel expression vectors and methods for the production thereof.
    Type: Grant
    Filed: September 16, 1996
    Date of Patent: March 10, 1998
    Assignee: Novartis Corporation
    Inventors: Jutta Heim, Peter Furst, Thomas Hottiger, Jochen Kuhla, Gabriele Pohlig
  • Patent number: 5717058
    Abstract: The present invention relates to regulators of cellular gene transcription, particularly inhibitors of cellular gene transactivating factors and in particular to inhibition of gene transcription in a viral host cell that is subject to regulation by proteins or factors that originate from a virus as well as conjugates or fusion products of the inhibitors and internalization molecules, pharmaceutical compositions that can be used to alleviate or prevent the manifestation of disease states that are the result of unregulated DNA transcription as a result of transactivation, methods of treating diseases that are caused or exacerbated by the presence of transactivating factors, and regulated gene therapy to achieve long term drug delivery of the inhibitors of the present invention. This invention can be applied both to cells with genetic abnormalities or to cells infected with a virus. Preferably, at least one protein of the protein-protein interactions is a transactivating factor.
    Type: Grant
    Filed: February 18, 1994
    Date of Patent: February 10, 1998
    Assignee: Somatogen, Inc.
    Inventors: Maura-Ann H. Matthews, Gary L. Stetler, Spencer J. Anthony-Cahill, David C. Anderson
  • Patent number: 5708140
    Abstract: The invention lies in the field of genetic engineering and, in particular, is concerned with the use of 7B2 as chaperone in vivo or in vitro. The invention accordingly concerns a method for producing a desired protein in vivo with the aid of recombinant cells capable of expressing 7B2 and of expressing and secreting said desired protein. Another aspect is accordingly an in vitro method for the deaggregation or prevention of aggregation of protein by treating the protein with 7B2.
    Type: Grant
    Filed: September 2, 1994
    Date of Patent: January 13, 1998
    Assignee: Ciba-Geigy Corporation
    Inventors: Gerardus Julianus Maria Martens, Bhabatosh Chaudhuri, Christine Stephan
  • Patent number: 5702920
    Abstract: The invention concerns polypeptides related to human macrophage migration inhibition factor, in particular the polypeptides called MRP-8 and MRP-14, processes for their preparation, mRNAs, DNAs and hybrid vectors coding for those polypeptides, hosts transformed with such a hybrid vector, monoclonal and polyclonal antibodies to those polypeptides, and diagnostic methods for inflammatory conditions and cystic fibrosis.
    Type: Grant
    Filed: July 27, 1995
    Date of Patent: December 30, 1997
    Assignee: Novartis Corporation
    Inventors: Karel Gerrit Odink, Roger Clerc, Nico Cerletti, Josef Bruggen, Lajos Tarcsay, Clemens Sorg, Walter Wiesendanger
  • Patent number: 5683997
    Abstract: The invention relates to substituted 3-amino-1-arylalkyl-benzazepin-2-ones of the general formula ##STR1## wherein the substituents are defined in the specification; or salts thereof; to processes for the preparation thereof; and to the use thereof as well as to pharmaceutical compositions that comprise compounds of formula (I) or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 9, 1995
    Date of Patent: November 4, 1997
    Assignee: Ciba-Geigy Corporation
    Inventors: Peter Buhlmayer, Pascal Furet
  • Patent number: 5665869
    Abstract: The present invention relates to a method for the production of a substantially protoporphyrin IX free hemoglobin solution comprising: rapidly heating a crude protoporphyrin IX-containing hemoglobin solution for a relatively short time and at a relatively high temperature to reduce protoporphyrin IX-containing hemoglobin to insignificant levels in said protoporphyrin IX-containing hemoglobin solution.
    Type: Grant
    Filed: November 15, 1993
    Date of Patent: September 9, 1997
    Assignee: Somatogen, Inc.
    Inventors: James R. Ryland, Maura-Ann H. Matthews, Ulrich P. Ernst, Daniel E. Houk, David W. Traylor, Lee R. Williams